Amanda Ridley

Has grant

The University of Manchester
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Characterising the expression of the chemokine CXCL4 (platelet factor 4) and glycosaminoglycans during the development of peritoneal fibrosis in patients on dialysis

Open Date: 2024-12-01

Close Date: 2025-06-01

Grant: Close

Characterising the expression of the chemokine CXCL4 (platelet factor 4) and glycosaminoglycans during the development of peritoneal fibrosis in patients on dialysis

Open Date: 2024-12-01

Close Date: 2025-12-01

Grant: Close

Characterising the expression and function of CXCL4 at rest and during inflammation

Open Date: 2024-06-01

Close Date: 2024-07-01

Grant: Close

Investigating the function and importance of macrophage derived CXCL4 during pulmonary allergic inflammation

Open Date: 2023-10-01

Close Date: 2024-10-01

Grant: Close

Defining the expression and function of CXCL4 during rest and inflammation in vivo

Open Date: 2023-05-01

Close Date: 2024-05-01

Articles (6)

The glycocalyx is a proteoglycan-rich layer present on the surface of all mammalian cells and is particularly prevalent on endothelial cells lining the vasculature. The glycocalyx is thought to affect leukocyte migration by masking adhesion molecules and reducing leukocyte adhesion to the endothelium. Leukocyte recruitment is a key driver of inflammatory diseases, including psoriasis. Here, we found that leukocytes had the glycocalyx component heparan sulfate on their cell surface and that it was lost in response to psoriasis-like skin inflammation. In contrast, endothelial heparan sulfate was not affected. Treatment with a heparan sulfate mimetic during psoriasis-like skin inflammation in mice protected heparan sulfate from cleavage by myeloid cell–derived heparanase and resulted in reduced leukocyte accumulation in the skin. However, clinical signs of inflammation were increased because of the reduced numbers of T regulatory cells that were recruited. These findings refine our understanding of immune cell recruitment by revealing the presence and function of a heparan sulfate glycocalyx on immune cells and highlight the complex effects of heparanase inhibitors on the immune response in this context.

Year:

2025

Macrophage activation is underpinned by metabolic changes required to fight infection, resolve inflammation and enable effective wound healing. While metabolic control of macrophage activation is increasingly understood in culture systems in vitro , it remains poorly understood in more complex in vivo settings, like the lung. Here we applied novel flow cytometry based immunometabolic techniques to profile immune cell metabolism in the murine lung. We revealed a surprising role for glucose in naïve alveolar macrophages (AMs) that was retained by AMs polarised in vivo with either interleukin-4 (IL-4) or lipopolysaccharide (LPS). We identified that naïve interstitial macrophages (IMs) were dependent on mitochondrial and glucose metabolism, IMs polarised with IL-4 failed to induce metabolic alterations but displayed a glycolytic phenotype following LPS exposure as they adopted an ‘M1’ like metabolic profile. We also demonstrated that AMs were metabolically less responsive than IMs to intranasal delivery of LPS, but upregulated glycolysis and metabolic features of ‘M2’ polarisation (defined in vitro ) in response to intranasal IL-4, including oxidative phosphorylation (OXPHOS), fatty acid oxidation (FAO) and arginine metabolism. Finally, we identified AM M2 polarisation as highly sensitive to glucose inhibition ex vivo . Thus, lung macrophage subsets display distinct metabolic responses to polarising stimuli in vivo . Highlights Naïve alveolar macrophages require glucose metabolism despite residing in a low glucose environment. Alveolar macrophages are more responsive to IL-4 in vivo than LPS upregulating oxidative metabolism, lipid metabolism and glycolysis. Interstitial macrophages adopt a glycolytic phenotype characteristic of ‘M1’ BMDMs in vitro following in vivo LPS administration. Alternatively activated alveolar macrophages are extremely sensitive to glucose inhibition ex vivo .

Year:

2025

Although human lung macrophages are heterogenous and play key roles during health and disease, the mechanisms that govern their activation and function are unclear, particularly in type 2 settings. Our understanding of how human lung macrophages respond to inflammatory signals have predominantly relied on cell lines or peripheral blood derived cells, which have a limited capacity to reflect the complexity of tissue macrophage responses. Therefore, we isolated macrophages from resected human lung tissue and stimulated them ex vivo under type 2 (IL-4, IL-13, or IL-4 + IL-13) or type 1 (IFNγ + LPS) conditions. Human lung macrophages stimulated with IL-4/13, alone or in combination, significantly upregulated expression of the chemokines CCL17 , CCL18 and CCL22, along with the transglutaminase TGM2 and the lipoxygenase ALOX15 . This type 2 activation profile was distinct from LPS + IFNγ activated human lung macrophages, which upregulated IL6 , IL8 , IL1β , TNFα and CHI3L1 (YKL-40). Further, type 2 activated human lung macrophage products showed differential metabolic reliance for their induction, with IL-4/13 induced CCL22 being glycolytically controlled, while ALOX15 was regulated by fatty acid oxidation. These data clarify hallmarks of human lung macrophage activation and polarisation in addition to revealing novel metabolic regulation of type 2 markers.

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Iashia Nabi

The University of Manchester

UNITED KINGDOM
View details

Karl Hoffmann

Aberystwyth University

UNITED KINGDOM
View details

Rafael J Argüello

CRCN

CNRS Délégation Côte d'Azur

FRANCE
View details

Rebecca Miller

Associate Professor

University of Copenhagen

DENMARK
View details

Olga V. Zubkova

Programme Leader, Senior Scientist

Victoria University of Wellington

NEW ZEALAND
View details

Peter Cook

University of Exeter

UNITED KINGDOM
View details

Douglas Dyer

The University of Manchester

UNITED KINGDOM
View details

Ingo Schiessl

The University of Manchester

UNITED KINGDOM
View details

Angela Simpson

The University of Manchester

UNITED KINGDOM
View details

Nabina Pun

University of Oxford

UNITED KINGDOM
View details

Andrew S MacDonald

The University of Manchester

UNITED KINGDOM
View details

Max Nobis

Head

UCL Cancer Institute

BELGIUM
View details

Stefano Adriano Colombo

The University of Manchester

UNITED KINGDOM
View details

Emma Houlder

Leiden University Medical Center

NETHERLANDS
View details

Jan Pieter Koopman

University of Oxford

UNITED KINGDOM
View details